The association of mycophenolate mofetil and human herpes virus infection
- PMID: 30676825
- DOI: 10.1080/09546634.2019.1572864
The association of mycophenolate mofetil and human herpes virus infection
Abstract
Purpose: Mycophenolate mofetil (MMF) is a steroid-sparing immunosuppressant used extensively to treat both common and rare dermatological conditions. Its lymphocyte specificity makes it a favorable therapeutic option particularly for patients who cannot tolerate alternative immunosuppressants. However, the side effect profile of MMF has not been extensively evaluated. This review presents current evidence regarding increased risk of human herpesvirus infection (HHV) with MMF therapy.Methods: The electronic database Medline (OVID) was searched on January 2018 for relevant English-language articles regarding the evaluation of incidence/prevalence of HHV infection in patients taking MMF, identifying 24 studies.Results: The majority of available studies were conducted on solid organ transplant recipients receiving complex immunosuppressive treatment including the MMF. Cytomegalovirus is the most well studied of the HHV. A positive association with cytomegaloviruses was found with MMF when compared to alternative immunosuppressants and studies to date suggest dose-dependent effect.Conclusion: MMF is a commonly used steroid-sparing agent used to treat dermatological conditions. This review highlights that MMF is positively associated with cytomegalovirus infection. The presented studies were heterogeneous in study design and detection method, with the majority completed on renal transplant patients. Further studies are needed to shed light on the association of MMF with HHV.
Keywords: Mycophenolate mofetil; human herpesviruses; immunosuppression; opportunistic infection.
Similar articles
-
Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?--A mini-review.Braz J Infect Dis. 2006 Apr;10(2):132-8. doi: 10.1590/s1413-86702006000200011. Braz J Infect Dis. 2006. PMID: 16878265 Review.
-
Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses.Clin Transplant. 1998 Jun;12(3):198-205. Clin Transplant. 1998. PMID: 9642510 Clinical Trial.
-
Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.Transpl Infect Dis. 2010 Feb;12(1):23-30. doi: 10.1111/j.1399-3062.2009.00448.x. Epub 2009 Sep 9. Transpl Infect Dis. 2010. PMID: 19744284 Clinical Trial.
-
Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.Clin Transplant. 2000 Aug;14(4 Pt 2):413-20. doi: 10.1034/j.1399-0012.2000.14041002.x. Clin Transplant. 2000. PMID: 10946781
-
The use of mycophenolate mofetil in transplant recipients.Immunopharmacology. 2000 May;47(2-3):215-45. doi: 10.1016/s0162-3109(00)00190-9. Immunopharmacology. 2000. PMID: 10878291 Review.
Cited by
-
Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19: A case report.Medicine (Baltimore). 2020 Jun 12;99(24):e20481. doi: 10.1097/MD.0000000000020481. Medicine (Baltimore). 2020. PMID: 32541471 Free PMC article.
-
Antiviral Drugs Screening for Swine Acute Diarrhea Syndrome Coronavirus.Int J Mol Sci. 2022 Sep 24;23(19):11250. doi: 10.3390/ijms231911250. Int J Mol Sci. 2022. PMID: 36232553 Free PMC article.
-
The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.Curr Dermatol Rep. 2023;12(2):45-55. doi: 10.1007/s13671-023-00385-w. Epub 2023 Apr 3. Curr Dermatol Rep. 2023. PMID: 37304177 Free PMC article. Review.
-
Research Advances on Swine Acute Diarrhea Syndrome Coronavirus.Animals (Basel). 2024 Jan 30;14(3):448. doi: 10.3390/ani14030448. Animals (Basel). 2024. PMID: 38338091 Free PMC article. Review.
-
Effect of Immunosuppressive or Immunomodulatory Agents on Severe COVID-19 Outcomes: A Population-Based Cohort Study.ACR Open Rheumatol. 2023 Dec;5(12):685-693. doi: 10.1002/acr2.11620. Epub 2023 Oct 11. ACR Open Rheumatol. 2023. PMID: 37818772 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources